United States: OIG Releases Supplemental Guidance For Bona Fide, Charitable Patient Assistance Programs

Last Updated: May 23 2014
Article by Larri A. Short and Stephanie Trunk

On May 21, 2014, the Department of Health and Human Services Office of Inspector General (OIG) released a Supplement Specialty Advisory Bulletin entitled "Independent Charity Patient Assistance Programs" (the Supplemental SAB, available here), to supplement its Special Advisory Bulletin on Patient Assistance Programs for Medicare Part D Enrollees (2005 SAB) (70 Fed. Reg. 70623) (Nov. 22, 2005, available here). The OIG was very clear that the additional guidance was not meant to replace the 2005 SAB or any other guidance. However, in several aspects, as explained below, Supplemental SAB modifies existing OIG advisory opinions provided to many bona fide independent charitable patient assistance programs (PAPs). As explained in the Supplemental SAB, the OIG has sent notices to all charitable PAPs currently holding favorable OIG advisory opinions requiring additional certifications from some and potential modifications for others.

The OIG states that the Supplemental SAB has been informed by its experiences with the Medicare Part D program from its inception in 2006 until present. In the recent past, some charitable PAPs have come under media scrutiny for allegedly favoring donor brand name drugs over generic equivalents and other therapeutic alternatives and in defining disease-specific funds too narrowly. In addition, some pharmaceutical manufacturer donors have received federal government inquiries related to their donations to certain charitable PAPs. The OIG has focused its supplemental guidance on three areas: Disease funds, eligible recipients, and the conduct of donors, which we review in turn below.

Disease Funds

Given recent media scrutiny, it is not surprising that the OIG focused the overwhelming majority of the Supplemental SAB on how charitable PAPs define disease-specific funds. The OIG states that the federal Anti-Kickback Statute (AKS) (42 U.S.C. § 1320-7b) is implicated if a pharmaceutical manufacturer donor is able to use a disease-specific fund as a conduit for payments to patients related specifically to the use of the manufacturer's drug. As such, if a PAP defines a disease-specific fund too narrowly, such that only one drug is a potential treatment for the underlying disease, the fund could be a conduit for a pharmaceutical manufacturer donor to provide remuneration only to consumers utilizing its drug, which squarely implicates the AKS.

In its 2005 SAB, the OIG articulated that is would be concerned about disease-specific funds which were defined by reference to specific symptoms, severity of symptoms or the method of administration of drugs. The Supplemental SAB makes clear that those were merely examples and not "an exclusive list." The OIG states it will scrutinize any narrowly defined disease-specific fund, particularly if the narrow definition results "in funding exclusively or primarily the products of donors..." Specifically, the OIG highlighted that funds which are defined by the stages of a particular disease or the type of drug treatment were too narrowly defined.

In addition, the OIG expressed concern about charitable PAPs that utilized high cost-sharing thresholds, such as $100 per prescription or the like, to narrow drug coverage under their funds, thus favoring coverage for high-priced brand drugs and often specialty products over lower cost generic drugs. While the OIG recognized that many charitable PAPs used these thresholds to preserve their resources for the neediest patients, its felt such a practice could result in steering patients to certain higher-priced drugs and facilitate the ability of manufacturers to charge higher prices for their products. As such, the OIG stated a fund would be subject to increased scrutiny "if it was limited to a subset of available products rather than all products approved by the Food and Drug Administration for treatment of the disease state(s) covered by the fund..."

Lastly, the OIG states emphatically in the Supplemental SAB that "a disease fund that covers only a single product, or the products made or marketed by only a single manufacturer that is a major donor to the fund, will be subject to scrutiny." Given the OIG's declaration, it seems the OIG is suggesting that a charitable PAP — with a fund specific to an orphan disease where there is only one available drug treatment, manufactured by one pharmaceutical manufacturer who is also the fund's sole donor — may violate the AKS.

Eligible Recipients

In the Supplemental SAB, the OIG affirmed that independent charitable PAPs with properly structured disease-state funds could operate funds that provide cost-sharing assistance only to Medicare and other Federal Health Care Program beneficiaries. It reiterated that eligibility for assistance must be determined using reasonable, verifiable and uniform measures of financial need, applied in a consistent manner. The OIG emphasized that the cost of a particular drug should not be considered in a vacuum when assessing financial need but, if considered at all, would have to be part of a broader assessment of financial need.

Conduct of Donors

In the Supplemental SAB, the OIG highlighted that advisory opinions issued to PAPs are binding solely upon the PAPs to which they were issued and not their donors. Charitable PAPs are not protected by their current advisory opinions, unless they follow all of the certifications that form the basis of their advisory opinions including defining all disease-state funds in accordance with widely recognized clinical standards and limited data provided to donors about fund distributions to aggregate information that cannot be correlated with the spending on any particular manufacturer's drug. It also stated that any actions taken by donors to "correlate their funding of PAPs with support for their own products" may be "indicative of donor's intent to channel its financial support to copayments of its own products, which would implicate the [AKS]."

The Supplemental SAB includes only the OIG's opinions as to implications of charitable PAP practices under the AKS and beneficiary inducement statute, not the federal False Claims Act or other federal or state laws.

It is imperative that all charitable PAPs critically review how their disease-specific funds are defined to ensure compliance with their current OIG advisory opinions, if applicable, as well as the OIG's 2005 SAB and this Supplemental SAB and respond to the OIG's request for additional certifications or modification discussions in timely fashion. Pharmaceutical manufacturer donors to charitable PAPs should review their current donation practices, donor agreements and oversight of chartable PAPs to which they contribute for compliance with all OIG guidance, including this Supplemental SAB.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions